Sign in

CIK 0000715446

  • Non-accelerated filer
  • Smaller reporting company

Anixa Biosciences Inc

Sign in to watch
Ticker
ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Oct 31
Incorporated
DE
Entity type
Operating
EIN
112622630
Phone
+1 408-708-9808
Business address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Former names
ITUS Corp, COPYTELE INC
  1. 4 Open-market buy Director bought 210,000 shares at $0.11 ($23,835)
  2. 4 Open-market buy Director bought 54,958 shares at $0.15 ($8,139)
  3. 4 Open-market buy Director bought 175,000 shares at an average $0.16 ($27,262)
  4. 4/A Open-market buy Director bought 100,000 shares at an average $0.15 ($14,725)
  5. 4 Open-market buy President and CEO bought 80,000 shares at an average $0.15 ($11,824)
  6. 4 Open-market buy Director bought 100,000 shares at an average $0.15 ($14,725)
  7. 4 Open-market buy Director bought 15,000 shares at $0.13 ($1,901)
  8. 4 Open-market buy Director bought 280,000 shares at an average $0.13 ($37,796)
  9. 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($20,920)
  10. 4 Open-market buy President and CEO bought 130,000 shares at an average $0.13 ($17,310)
  11. 4 Open-market buy Director bought 50,000 shares at $0.15 ($7,500)
  12. 4 Open-market buy Director bought 25,000 shares at $0.14 ($3,450)
  13. 4 Open-market buy President and CEO bought 25,000 shares at $0.14 ($3,558)
  14. 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($21,720)
  15. 4 Open-market buy President and CEO bought 20,000 shares at an average $0.14 ($2,848)
  16. 4 Open-market buy Director bought 42,000 shares at $0.14 ($5,922)
  17. 4 Open-market buy Director bought 36,000 shares at $0.14 ($5,040)
  18. 4 Open-market buy Director bought 136,025 shares at $0.16 ($21,220)
  19. 4 Open-market buy President and CEO bought 20,000 shares at $0.16 ($3,250)
  20. 4 Open-market buy Director bought 25,000 shares at $0.16 ($4,000)

Page 15 of 24 · 471 filings